Zhaoke Ophthalmic (å ē§ē¼ē§) IPO Trading: Strong Cornerstone Doesn't Save the Deal
We re-iterate our differentiated bearish view with the deal. The deal received lukewarm interests from retail and institutional investors. We would...
463 Views
Zhaoke Opthalmology IPO Valuation: Overpriced
Some of the companyās drug candidates have the potential to become market-leading products, however, Zhaoke does not have any prior experience in...
418 Views
ECM Weekly (18th April 2021) - ByteDance Zhaoke, We Doctor, Medlive, Bio-Thera, Grab, Ngern Tid Lor
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
496 Views
Zhaoke Ophthalmology IPO: Valuation Insights
Zhaoke has launched an HKEx IPO to raise net proceeds of $239m at the mid-point of the IPO price range of HK$15.38-16.80 per share. Overall, we...
562 Views
Zhaoke Ophthalmic (å ē§ē¼ē§) IPO: Rationalize the Valuation
We think the valuation is rich at the high end and the cornerstone investors' commitment left a large portion of the deal to be sold on debut.
668 Views